In an organotypic human epidermis model, treatment with HMGB1 or IL-4 downregulates the expression of several proteins related to skin barrier function and increases production of IL-33, an inflammatory cytokine known to be upregulated in skin lesions of AD patients (90). The gene discussed is IL4; the disease is Alzheimer disease.